SCHEMBL7182230

SCHEMBL7182230

O=C(Pc1ccc(OCc2ccccc2)cc1)c1c(C(F)(F)F)cccc1C(F)(F)F.[LiH]

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
FFAR1 O14842 4/20 0.46
FFAR4 Q5NUL3 2/20 0.46
NR4A2 P43354 2/20 0.46
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
MRGPRX4 Q96LA9 2/20 0.45
MAOB P27338 4/20 0.45
PARP10 Q53GL7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188429 0.84 KMT2A (0.49) LMNAMRGPRX4MAOBPARP10
SCHEMBL7188798 0.83 MAPK14 (0.40) FFAR1MAOBPARP10
SCHEMBL7182430 0.83 MRGPRX4 (0.48) RXRARXRBRXRGFFAR1FFAR4
SCHEMBL7185527 0.82 MRGPRX4 (0.50) RXRARXRBRXRGFFAR1FFAR4
SCHEMBL7189087 0.82 PTGS1 (0.51) RXRARXRBRXRGLMNACYP1A2
SCHEMBL7177524 0.82 MRGPRX4 (0.45) RXRARXRBRXRGFFAR1MRGPRX4
SCHEMBL7181323 0.81 LMNA (0.41) LMNACYP1A2CYP2C19FFAR4MAOB
SCHEMBL7179835 0.81 FAAH (0.44) CYP1A2CYP2C19HIF1AHDAC6FFAR4
SCHEMBL7189867 0.81 HDAC4 (0.39) RXRARXRBRXRGLMNAFFAR1
SCHEMBL7185160 0.81 FFAR1 (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 RXRA 2745/4885RXRB 3027/4885RXRG 2912/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 RXRA 2809/4885RXRB 3240/4885RXRG 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.